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Abstract
Title: Advantages of Intravenous Administration of Amisulpride Over Ondansetron for
Prophylaxis of Postoperative Nausea and Vomiting: An Educational Module
Impact Statement: In patients undergoing general anesthesia, the administration of intravenous
amisulpride has proven to be effective in preventing Post Operative Nausea and Vomiting
(PONV) while having a safer profile when compared to ondansetron.
Background: PONV is, after pain, the second most frequent complaint after surgery, and it may
contribute to severe complications, decrease patient satisfaction, extend the hospital stay and
increase healthcare costs.1-6 Despite the potential for serious side effects, ondansetron remains
the preferred drug used to prevent PONV.5
Objective: This project aims to compare the effectiveness and safety profile of ondansetron and
amisulpride as a prophylaxis for PONV and present the findings through an educational module
to anesthesia providers and assess the degree of knowledge gained.
Method: We conducted a literature review comparing amisulpride and ondansetron as
prophylactic agents for PONV. We created an online educational module to present to anesthesia
providers and a pre and post surveys to assess the degree of knowledge acquired. The project
was developed in a large level 1 trauma center, using anonymous and online platform for survey
and module delivery and data collection.
Results: We found amisulpride to be effective as a prophylactic drug for PONV; it also
decreases the severity of nausea in the high-risk patient. Amisulpride has a safer profile and
fewer potential for side effects when compared to ondansetron.
Discussion: Data from surveys shows anesthesia providers increased their knowledge about
PONV and effective prophylaxis treatments after the educational module. Small sample size,
short duration of this project, and the use of online platform were limitations of this project.
Conclusion: The educational module improved anesthesia providers’ knowledge and attitude
about Postoperative Nausea and Vomiting and the administration of intravenous amisulpride as
an effective and safe prophylactic alternative.
Keywords: Postoperative Nausea and Vomiting, Prophylaxis, Prevention, Ondansetron,
Amisulpride, Postoperative Care
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Advantages of Intravenous Administration of Amisulpride Over Ondansetron for
Prophylaxis of Postoperative Nausea and Vomiting: An Educational Module
I. Introduction
Problem Identification
In addition to pain, Postoperative Nausea and Vomiting (PONV) is the second most
common complaint after a surgical procedure. Nausea is an unpleasant sensation referred to as a
desire to vomit without the muscular movement that produces expulsion, while vomiting is the
act of expulsing the gastric content.1 PONV is a distressing and frequent complication after
surgical procedures under anesthesia. It may contribute to dehydration, electrolyte abnormalities,
delayed wound healing and dehiscence, pulmonary aspiration of gastric content, and extended
hospital stay.2
Despite the widespread use of short-acting anesthetic agents, antiemetic drugs as
prophylaxis, and minimally invasive procedures, PONV still affects about 20% to 30% of
surgical patients. It could be as high as 80% in high-risk patients.3 One reason for the high
incidence of PONV is the increased number of ambulatory surgical procedures.3 There is an
extensive repertoire of literature supporting strategies to prevent PONV, but the optimal
recommendation has not been established.2
PONV is a multifaceted physiologic event including several pathophysiologic
mechanisms. The primary control of nausea and vomiting comes from the vomiting center,
located in the medulla. Five main receptor pathways are involved in the means of PONV: reflex
afferent pathways from the cerebral cortex, neuronal pathways from the vestibular system, the
chemoreceptor triggering zone, midbrain afferents, and the vagal mucosal track in the
gastrointestinal system. The vomiting center could be activated by stimulating any of these
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afferent pathways via serotonergic receptors, dopaminergic, cholinergic (muscarinic), or
histaminergic stimulation can activate the vomiting center.3
Gene aberrations can also increase the incidence of PONV incidence and influence the
response to prophylaxis or rescue treatment. The deletion of AAG in 5-HT3B receptor gene and
polymorphism on the A2A2 allele of the dopamine D2 receptor increases the frequency and
magnitude of PONV. In the presence of a phenotype of a rapid metabolizer, there is a higher
incidence of postoperative vomiting.4
Background
PONV is a secondary discomfort attributed ta surgery, as the pain remains a frequent
complaint after surgery. The following complications appear to result from PONV:
wound dehiscence, fluid and electrolyte imbalances, pneumothorax, pulmonary aspiration,
subcutaneous emphysema, esophageal lesions, excessive tension in the suture line, and high
intracranial pressure.5 The occurrence of complications is related to the duration of PONV, as
this may occur during the first 24 hours postoperatively, lasting for up to 3 days after the
procedure was finished.6
The risk factors of PONV include female gender, patients less than 50 years old,
gravidity, history of PONV or motion sickness, a body mass index less than 25 kg/m2,
nonsmoking patients, laparoscopic surgeries, procedures lasting ≥ 1 hour, and type of surgery.5
PONV seems to be related to general anesthesia, intravenous patient-controlled analgesia
and inhalational agents like enflurane or nitrous oxide, and administration of cholinergic or
opioid formulations.5 The administration of opioids, intraoperatively or postoperatively, is linked
to a two to four times higher incidence of PONV. Multimodal analgesia, including non-opioid
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drugs, decreases the risk considerably for PONV. The incidence of PONV increases
exponentially as more risk factors of PONV are present in the same patient.7
Enflurane and isoflurane are not used as much nowadays with the increasing use of
desflurane and sevoflurane, but preliminary studies have analyzed the impact on PONV when
desflurane or sevoflurane are administered.8 There is no consensus about the magnitude of
symptoms concerning some risk factors like smoking, age, or length of surgery.8 Risk scores that
apply in adults are not typically applicable in children. An alternative classification is known as
the Eberhard classification. It identifies predictors for PONV, which include: the duration of the
procedure longer than 30 minutes; children older than 3 years old; previous history of the PONV
in child, parent, or siblings; and strabismus surgery.8 One point is given for each risk factor,
resulting in 0, 1, 2, 3, or 4 points, predicting the risk for PONV from 9% to up to 70%.9
The incidence of PONV in young children is minimal but increases significantly in
adolescents, in which the incidence surpasses that for adults. The type of procedure also plays a
role in the incidence of PONV. The most significant incidence seen is seen in children
undergoing hernia repair, strabismus repair, orchiopexy, microtia, tonsillectomy, and middle ear
surgeries. There are no significant differences between genders before puberty; PONV is
experienced in females more than in males after puberty.10
Most antiemetic drugs target one or more of the receptors activated in the mechanism of
nausea. This includes serotonin, opioid, histamine, dopamine, and muscarinic. Patients with
minor risk factors benefit from prophylaxis based on preference, cost-related factors, and
risk/benefit ratio. Patients at moderate and higher risks are benefited from the prevention of
PONV using at least 2 antiemetics. It is also valuable for the administration of Total Intravenous
Anesthesia (TIVA) with propofol and opioid-sparing formulations.5 A combination of
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antiemetics is used; drugs acting in different receptors seem to improve the efficacy of the
therapy.5
An additive result in reducing the incidence of PONV can be achieved by combining
different class antiemetics.11 Other recommendations combine pharmacologic and
nonpharmacologic options, and to decrease severity or eliminate modifiable factors. The use of
propofol, when compared to volatile anesthetics, reduces the incidence of postoperative nausea
and vomiting by 19%. The abstention from nitrous oxide additionally reduced the incidence of
PONV by 12%.12
Current guidelines on the management of PONV recommend risk-oriented, prophylactic
modalities based on predictive models, considering unnecessary costs and potential side effects,
in contrast to prescribing multiple agents to all patients. Although several prediction models are
well researched and frequently used, their practical impact is still being doubted since the
occurrence of PONV is still high despite the use of prophylactic agents.13
Scope of the Problem
Every year, about 20 million people suffer PONV around the globe. PONV and pain are
the 2 most common problems after surgery under anesthesia. Adult patients frequently rate
PONV as worse than pain. Many studies concluded that the incidence of PONV is highest in the
first 6 hours after the surgical procedure is completed.14 PONV is the principal reason for
unplanned hospital admission, extended hospital stays, and higher overall costs.15 It is also
significant the high level of discomfort and dissatisfaction in a from a patient suffering from
PONV.16

10
Consequences of the Problem
The magnitude of PONV varies from resource use to the significant physical and
psychosocial consequences on the patient. Direct and indirect costs are both increased with the
evidence of PONV in the surgical patient.17 Furthermore, the human component is essential for
most illnesses. From a hospital’s evaluation, the magnitudes of PONV are directly related to the
patient’s length of stay and resource utilization. From the patient’s point of view, the impact of
nausea and vomiting is significant during the postoperative recovery period and after discharge
in case of an outpatient encounter. PONV is unpleasant for the patient and includes the
debilitating component of the operation itself.18
Evidence-based guidelines encourage the use of pharmacological prophylaxis in patients
at risk of PONV. These guidelines provide recommendations on identifying high-risk patients,
managing baseline PONV risks, making choices for prevention and rescue treatment of PONV,
and offering suggestions for the institutional implementation of a PONV protocol.19 Ondansetron
remains the drug of choice for the prevention and treatment of PONV.5
Ondansetron hydrochloride is a selective inhibitor of type 3 serotonin receptors or 5HT3 receptors. It is preferred over other antiemetics by most anesthesia providers. When used as
a prophylaxis of PONV in adults, a 4 mg intravenous dose is recommended at least 30 minutes
before emergence from anesthesia. The half-life of ondansetron is usually about 4 hours;
therefore, it is recommended to administer it towards the end of the surgical procedure.5 Most
common side effects include headache, dizziness, diarrhea, elevated liver enzymes, and
constipation. Ondansetron is associated with QTc segment elongation and the potential increased
risk of cardiac arrest and arrhythmia.19

11
Knowledge Gaps
In 2020, the International Anesthesia Research Society released the Fourth Consensus
Guidelines for the management of PONV.9 In this edition, multimodal prophylaxis is
recommended with 2 or more methods. These recommendations are proposed due to the
inadequate prevention and the availability of antiemetic safety data. Ondansetron was proven to
be less efficacious than ramosetron, granisetron, palonosetron, aprepitant, and fosaprepitant.
Despite these facts, ondansetron continues to be the first choice, even when superior drugs are
available.9
While the efficacy of an intervention is reliable, effectiveness is influenced by
institutional compliance. Despite the efforts to widely adopt PONV management guidelines, its
implementation is insufficient in both adult and pediatric populations.20,21 Prompt management
of PONV requires constant vigilance. Still, it has been demonstrated that PONV symptoms are
often neglected, especially nausea. It has been documented that only 42% of postoperative
nausea and vomiting occurrences were acknowledged in the anesthesia care unit, and 29% were
diagnosed in the surgical team.22
Proposal Solution
In February 2020, the Food and Drug Administration (FDA) approved Barhemsys®
(amisulpride), from Acacia Pharma, as a prophylaxis and rescue treatment of PONV due to its
favorable results in clinical trials.23 Amisulpride is a dopamine D2, D3 receptors antagonist.
Amisulpride 5 mg intravenously was found to be more effective than placebo in achieving a
complete response and reducing the severity of nausea.9 Administration of amisulpride has been
associated with a mild increase in levels of prolactin, but the clinical importance remains unclear.
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A standard antiemetic dose of amisulpride is not associated with sedation, extrapyramidal side
effects, or QTc prolongation.24, 25, 26, 27
When intravenous amisulpride is given at induction of anesthesia in combination with a
standard antiemetic significantly decreases the incidence of PONV in a population of patients at
high risk of PONV undergoing a broad range of surgeries under general anesthesia using volatile
agents.24,25 Amisulpride, when used in combination with other class antiemetics, is well-tolerated
and has similar results compared to placebo in respect of safety profile.25 The effectiveness of
amisulpride as prophylaxis for PONV is higher when combined with dexamethasone than with
ondansetron.25
Rationale and Objective
To date, there is little information about studies directly comparing the efficacy of
ondansetron and amisulpride through randomized controlled trials. Nonetheless, there are
multiple randomized controlled trials comparing ondansetron to placebo and amisulpride to
placebo in similar populations, giving conclusive results on its effects as prophylaxis for PONV.
This literature review aims to investigate previous research on ondansetron and amisulpride,
individually compared to placebo, and gather statistically significant data to establish an
adjusted indirect comparison.28
II. Literature Review
Eligibility Criteria
Using inclusion and exclusion criteria, randomized controlled trials (RCT) were selected.
Inclusion criteria included only English written RCT, studying the effectiveness of either
Ondansetron or Amisulpride for prevention of PONV and compared to placebo. Exclusion
criteria included the studies where subjects were younger than 12 years of age, with preexisting
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nausea and vomiting 24 hours before the surgical procedure. Studies focused on prophylaxis of
PONV and the effect of drugs in the first 24 hours after the surgical procedure. Library services
at Florida International University (FIU) were used to access the database sources used for this
literature review.
Information Sources
The Cumulative Index to Nursing and Allied Health Literature (CINAHL), the Cochrane
Review Database (CRD), and PubMed were used as search tools. The Preferred Reporting
Items for Systematic Reviews and Meta-Analyses (PRISMA) guided this literature review.29

Screening

Identification

Identification of studies via databases and registers.29

Records identified from CINAHL,
CRD and PubMed:
From databases and
registers (n = 192)

Records removed before
screening:
Duplicate records removed (n
= 2)
Records marked as ineligible
by automation tools (n = 0)
Records removed for other
reasons (n = 0)

Records screened
(n = 190)

Records excluded (Not RCT)
(n = 172)

Reports sought for retrieval
(n = 18)

Included

Reports assessed for eligibility
(n = 10)

Studies included in review
(n = 6)

Reports not retrieved (unable to
obtain full report)
(n = 8)

Reports excluded:
Age < 12 years (n = 2)
Additional medication
administered (n = 2)

14
Search Strategy
Initially, 192 articles were identified. The search was refined to studies either comparing
ondansetron to placebo or amisulpride to placebo. Studies where the administration of
ondansetron was different than 4 mg were excluded. Studies where the administration of
amisulpride was other than 5 mg were excluded. The search was limited to studies measuring the
effectiveness of either ondansetron or amisulpride for preventing PONV in the initial 24 hours of
the postoperative period. Following these inclusion and exclusion criteria, 6 articles remained
and were analyzed.
Keywords
Based on the PICOT question, these search keywords were identified: postoperative
nausea and vomiting, prophylaxis, prevention, ondansetron, amisulpride, and postoperative care.
Figure 1. Search Keywords

Postoperative Nausea and
Vomiting

AND
Ondansetron
OR
Amisulpride

AND

Prophylaxis
OR
Prevention

AND

AND

Postoperative
Care
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Study Characteristics
Through the literature review, necessary data was collected from randomized controlled
trials, either comparing the effectiveness of ondansetron compared to placebo or amisulpride
compared to placebo in similar populations. Then, the data was used to establish an indirect
comparison. This method compares the effectiveness of two medications (ondansetron and
amisulpride) relative to a mutual comparator (placebo), which will associate these drugs.28
Results
The articles analyzed in this literature review evaluated the effect of the drug as
prophylaxis for PONV. The result of ondansetron on preventing PONV was investigated by So
et al.30, Kovak et al.31, and Mckenzie et al.32. In contrast, the impact of amisulpride on preventing
PONV was investigated by Kranke et al.24,25 and Gan et al.26 All the studies are prospective,
double-blind, randomized controlled trials.24-26,30-32 All the studies constitute evidence level I.33
In an investigation by So et al.,30 the authors randomized 68 patients to receive either a
single intravenous dose of 4 mg of ondansetron prior to extubation (36 patients) or no
prophylaxis (32 patients). An independent observer used a visual analog score to assess nausea
and vomiting for 24 hours after the surgical procedure. This study showed no difference between
the ondansetron (n = 36) and control (n = 32) groups. In the first two hours of the postoperative
period, two patients (6%) treated with ondansetron and one patient (3%) from the control group
experienced vomiting. At 24 hours, 5 patients (14%) were treated prophylactically with
ondansetron, and 6 patients (19%) from the control group vomited.30
Ten patients treated with ondansetron and 11 patients in the control group required rescue
treatment with antiemetic before discharge. The length of hospital stay and satisfaction rate was
similar between the two groups.30 Comparing these two groups, the occurrence of vomiting in
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the first 24 hours decreased by 5% in the group that received ondansetron as prophylaxis.30 The
authors concluded that the routine administration of ondansetron does not reduce the occurrence
of PONV after laparoscopic cholecystectomy.30
Kovac et al.31 conducted a multicenter, stratified study that analyzed 467 male patients
randomly treated with ondansetron, 4 mg intravenously (n = 242) or placebo (n = 225). The
complete responsibility for this study was defined as no emesis.31 In the initial 2 hours of the
postoperative period, 71 patients (31%) of the ondansetron group did not experience nausea,
compared to 63 patients (26%) in the placebo group. In the same period, 88 patients (39%)
treated with ondansetron remained vomit-free, compared to 63 patients (26%) in the placebo
group. In the overall 24-hour period, 59 patients treated with ondansetron (26%) did not
complain of nausea compared to 49 patients (20%) from the placebo group. At the end of the 24hour period, 80 patients (35%) did not have any emetic episode in the group treated with
ondansetron, while in the placebo group, 63 patients (26%) remained emesis free.31
The authors concluded that 4 mg of intravenous ondansetron prevents emesis effectively
in the male population. In the first 2 hours of the postoperative period, ondansetron reduced
nausea by 5% and vomiting by 6%. After an initial 24-hour period, the overall incidence of
nausea with ondansetron was decreased by 6%, while emesis was reduced by 9%.31
A prospective study by McKenzie et al.32 included 580 women, randomly assigned to 4
groups, and given ondansetron intravenously, 1 mg, 4 mg, 8 mg, and placebo. In this study, the
nurse asked the patient about the presence and severity of nausea and evaluated the objective
existence of an emetic episode. A data entry card was provided to the patient at discharge to
record nausea and emesis data, and cards were mailed back to the researcher.32
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In the postoperative period, 30% of patients in the placebo group (n = 139) did not
experience nausea, while 40% of the patients treated with ondansetron 4 mg (n = 136) remained
nausea-free for the same period. Similarly, 64 patients (77%) from the placebo group did not
have emesis or rescue treatment before discharge. They experienced no vomiting over the next
22 hours, compared to 103 patients (90%) from the ondansetron 4 mg group, without any
vomiting episode. The authors of this investigation conclude with the statement that ondansetron
4 mg prevents nausea and vomiting. In this study, when 4 mg of intravenous ondansetron is
administered, nausea and vomiting are reduced by 10% and 13%, respectively, in the first 24
hours.32
Gan et al.26 conducted two identical placebo-controlled and parallel-group phase III
studies to evaluate the efficacy of intravenous 5 mg of amisulpride in preventing PONV in the
adult post-surgical patient, where 689 patients were initially chosen for the administration of
intravenous amisulpride (5 mg) or equivalent to placebo; a total of 626 were evaluated, once 63
subjects were excluded. All the patients included in the studies have two or more risk factors for
PONV.26
During the first 24-hour period, 164 patients (52.1%) of the amisulpride pooled group
reported nausea, compared to 195 (62.7%) from the placebo pooled group. During the same
period, 68 patients (21.6 %) from the amisulpride group experienced emesis, while 81 patients
(26%) from the placebo group remained emesis-free.26 The authors agree with the conclusion
that 5 mg of intravenous amisulpride effectively reduces the incidence of PONV, while data
shows reduced nausea and vomiting by 10% and 4%, respectively, in the first 24 hours, in
patients with 2 or more risk factors.26
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A multicenter trial was conducted by Kranke et al.25 in 1,147 patients with at least 3 risk
factors for PONV. Patients randomly received 5 mg of intravenous amisulpride (572 patients) or
placebo (575 patients), with well-balanced characteristics between these 2 groups. This placebocontrolled trial took place in 29 countries and was registered on ClinicalTrials.gov. This study
was planned by the authors and Acacia Pharma Ltd. Clinical practice standards were followed. 25
After 24 hours after surgery, 330 patients (57.7%) of the group receiving amisulpride did
not experience any nausea and vomiting (complete response), compared to 268 patients (46.6%)
from the placebo group. There was an 11% reduction in the occurrence of PONV between them.
The study shows that 5 mg intravenous amisulpride prevents PONV.25
Kranke et al.24 conducted a study on 223 patients, randomized into four groups to receive
amisulpride 1 mg, 5mg, 20 mg, and placebo. This parallel-group study was conducted at ten
international sites, including the United States. The trial was registered at EudraCT and
ClinicalTrials.gov. All the patients have two or more risk factors for PONV. A total of 215
patients were analyzed as protocol after eight candidates were excluded from the study.24
From the amisulpride 5 mg group (n = 50), 14% of the patients experienced PONV in the
24-hour postoperative period, compared to 69% of patients from the placebo group (n = 54); this
shows a reduction of PONV by 29% when amisulpride 5 mg was administered intravenously.24
The incidence of vomiting decreased from 35% (placebo group) to 14% (with amisulpride 5 mg),
for a 21% reduction. Similarly, nausea was reported in 72% receiving placebo, while 44% of
patients receiving amisulpride 5 mg intravenously reported any nausea, for a 27% reduction after
administration of amisulpride.24 The authors believe this study demonstrates a significant benefit
of amisulpride 5 mg intravenously for reduction of incidence of PONV.24
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Purpose

To analyze the
efficacy of
intravenous
ondansetron
for
prophylaxis of
Postoperative
Nausea and
Vomiting
(PONV) after
laparoscopic
cholecystecto
my

To study the
efficacy and
safety of
ondansetron in
preventing
PONV in male
outpatients

Methodology/
Research
Design
Prospective,
Double-blind,
Randomized
Controlled Trial
(RCT).
Level of
Evidence I.

Prospective,
Multicenter,
Stratified, RCT.
Level of
Evidence I.

Sampling/Setting

Primary Results

Relevant Conclusions

68 adult patients
received either 4
mg of intravenous
ondansetron (36
patients) or placebo
(32 patients).
Patient’s age was
21 to 82.
Patients were ASA
physical status I or
II.

During the first 2 hours
after surgery, 2 patients
(6%) from the ondansetron
group and 1 patient (3%),
from the control group,
experienced vomiting. At
24 hours, 5 patients (14%)
were treated
prophylactically with
ondansetron, and 6 patients
(19%) from the control
group vomited.

The study concluded
that the administration
of intravenous (4 mg)
of ondansetron does not
decrease incidence of
PONV.

467 male
outpatient, 12 year
and older.
242 patients
received
ondansetron 4 mg
intravenously.

10 patients treated with
ondansetron and 11
patients in the control
group required rescue
treatment with antiemetic
before discharge. The
length of hospital stay and
satisfaction rate was
similar between the 2
groups.
In the initial 2 hours of the
postoperative period, 71
patients (31%) of the
ondansetron group did not
experience nausea,
compared to 63 patients
(26%) in the placebo

The authors concluded
that 4 mg of
intravenous
ondansetron prevents
emesis effectively in
male population. In the
first 2 hours of the
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225 patients
received the
equivalent to
placebo.
This multicenter
study was
developed through
24 medical centers.
Patients were ASA
physical status I or
II.

McKenzie et
al.,32 1993

To study the
efficacy of
ondansetron
for
prophylaxis of
PONV in
women
undergoing
ambulatory
gynecologic
surgery

Prospective,
Double-blind,
Randomized
Controlled Trial
(RCT).
Level of
Evidence I.

580 patients
received either
ondansetron
intravenously (n =
438) or intravenous
equivalent to
placebo (n = 142).
68 adult patients
received either 4
mg of intravenous
ondansetron (36

group. In the same period,
88 patients (39%) treated
with ondansetron remained
vomit-free, compared to 63
patients (26%) in the
placebo group. In the
overall 24-hour period, 59
patients treated with
ondansetron (26%) did not
complain of nausea
compared to 49 patients
(20%) from the placebo
group. At the end of the
24-hour, 80 patients (35%)
did not have any emetic
episode in the group
treated with ondansetron,
while in the placebo group,
63 patients (26%) remained
emesis free
In the postoperative period,
30% of patients in the
placebo group (n = 139)
did not experience nausea,
while 40% of the patients
treated with ondansetron 4
mg (n = 136) remained
nausea-free for the same
period. Similarly, 64
patients (77%) from the
placebo group did not have
emesis or rescue treatment
before discharge. They

postoperative period,
ondansetron reduced
nausea by 5% and
vomiting by 6%. After
initial 24-hour period
the overall incidence of
nausea with
ondansetron was
decreased by 6%, while
emesis was reduced by
9%.

The authors of this
investigation conclude
with the statement that
ondansetron 4 mg
prevents nausea and
vomiting. In this study,
when 4 mg of
intravenous
ondansetron is
administered, nausea
and vomiting are
reduced by 10 and
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Gan et al.,26
2017

To evaluate
the efficacy of
intravenous
amisulpride in
the prevention
of PONV in
adult surgical
patients

2 identical and
concurrent,
Prospective,
Randomized,
Double-blind,
Placebocontrolled Trials.
Level of
Evidence I.

Kranke et
al,25 2018

To analyze the
efficacy of
intravenous
amisulpride in
the prevention
of PONV in
adult surgical
patients at
high risk

International,
Multicenter,
Prospective,
Double-blind,
Randomized,
Placebocontrolled Trial.
Level of
Evidence I.

patients) or placebo
(32 patients).
Patients were
between 18- and
70-year-old.
Patients were ASA
physical status I or
II.
689 patients were
randomized to
receive either 5 mg
of amisulpride
intravenously (n =
345) or placebo (n
= 344).
Age ranged
between 18 and 88
years.

1147 patients with
at least 3 PONV
risk factors
received either 5
mg of intravenous
amisulpride (n =
572) or placebo (n
= 575).
Patients were, at
least, 18-year-old.

experienced no vomiting
over the next 22 hours,
compared to 103 patients
(90%) from the
ondansetron 4 mg group,
without any vomiting
episode.

13%, respectively, in
the first 24 hours.

During the first 24-hour
period, 164 patients
(52.1%) of the amisulpride
pooled group reported
nausea, compared to 195
(62.7%) from the placebo
pooled group. During the
same period, 68 patients
(21.6 %) from the
amisulpride group
experienced emesis, while
81 patients (26%) from the
placebo group remained
emesis-free.
After 24 hours after
surgery, 330 patients
(57.7%) of the group
receiving amisulpride did
not experience any nausea
and vomiting (complete
response), compared to 268
patients (46.6%) from the
placebo group. There was
an 11% reduction in the
occurrence of PONV

The authors agree with
the conclusion that 5
mg of intravenous
amisulpride effectively
reduce the incidence of
PONV, while data
shows a reduced nausea
and vomiting by 10 and
4%, respectively, in the
first 24 hours, in
patients with 2 or more
risk factors.

The authors concluded
that 5 mg of
intravenous
amisulpride is safe and
efficacious for the
prevention of PONV,
in high-risk patients for
PONV.
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The trial took place
in 29 countries.

Kranke et
al.,24 2013

To evaluate
the efficacy of
intravenous
amisulpride in
the prevention
of PONV in
adult surgical
patients

Prospective,
Randomized,
Double-blind,
Placebocontrolled,
Multicenter
Trial.
Level of
Evidence I.

223 adult patients
were randomized to
receive either
amisulpride
intravenously (n =
168) (in doses of 1,
5, and 20 mg) or
placebo (n = 55)

between them. The study
shows that 5 mg
intravenous amisulpride
prevents PONV.
From the amisulpride 5 mg
group (n = 50), 14% of the
patients experienced
PONV in the 24-hour
postoperative period,
compared to 69% of
patients from the placebo
group (n = 54); this shows
a reduction of PONV by
29% when amisulpride 5
mg was administered
intravenously.13 The
incidence of vomiting
decreased from 35%
(placebo group) to 14%
(with amisulpride 5 mg),
for a 21% reduction.
Similarly, nausea was
reported in 72% receiving
placebo, while 44% of
patients receiving
amisulpride 5 mg
intravenously reported any
nausea, for a 27%
reduction after
administration of
amisulpride.

The authors believe this
study demonstrates a
significant benefit of
amisulpride 5 mg
intravenously for
reduction of incidence
of PONV.
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Discussion/Summary of Evidence
Since its approval by the FDA on October 31, 1997, ondansetron has been administered
in various formulations and dosages to prevent and treat nausea and vomiting.34 Prevention of
PONV is one of the most common ondansetron uses and is currently the most frequently
prescribed medication for this postoperative complication.35 The administration of 5 mg
intravenously remains the most accepted and often used dose of ondansetron, before emergence
from anesthesia, when used as prevention of PONV.35
Despite the widespread use of ondansetron, So et al.30 did not find significant differences
in preventing PONV compared to placebo in the first 24 hours. Still, during the first two hours
after surgery, the occurrence of vomiting was reduced by 5% when ondansetron was
administered.30 Kovak et al.31 also compared ondansetron to placebo, demonstrating the drug’s
effect by decreasing the occurrence of nausea and vomiting in two hours after the surgical
procedure by 5% and 6% respectively, while in the 24 hours, nausea and vomiting were reduced
by 6 and 9% respectively.20 McKenzie et al.21 also investigated the effect of ondansetron 4 mg
intravenously and compared it to placebo, concluding with the statement ondansetron lowers the
frequency of nausea and vomiting by 10% and 13%, respectively, in the first 24 hours.32
Commercialization and administration of amisulpride started in February 2020 after its
approval by the FDA. Its safety profile and effectiveness for prophylaxis of PONV impulse its
adoption by anesthesia providers working towards an enhanced recovery after surgery,
preventing the negative feelings with PONV, its complications, and increasing patient
satisfaction.35 Its cost-effectiveness also determines its success in the U.S. healthcare system,
where most institutions prefer to administer more profitable formulations.36
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In their study, Gan et al.26 found a reduction of nausea and vomiting by 10% and 4%,
respectively, in the first 24 hours when amisulpride 5 mg intravenously was administered before
the emergence of anesthesia when compared to placebo.26 Kranke et al.25 also investigated the
effectiveness of intravenous amisulpride compared to placebo, lowering by 11% the overall
incidence of PONV in 24 hours.25 In another randomized placebo-controlled trial, Kranke et al.24
found a decrease in the occurrence of overall PONV in 24 hours by 29% after administration of
intravenous amisulpride. While individually, nausea and vomiting were reduced by 27% and
35%, respectively, during the same 24-hour period.24
Conclusions
PONV not only represents an unpleasant experience and complication from a surgical
procedure, but it can negatively influence the patient's physical and mental recovery. Anesthesia
providers employ various measures to prevent PONV, including the administration of an
antiemetic or the combination of more than one. Ondansetron is currently the most prescribed
antiemetic for the prevention of PONV. Ondansetron is proven to reduce the incidence of PONV,
but several side effects are associated with its administration, with the most common being
headache, dizziness, diarrhea, raised liver enzymes, and constipation. Ondansetron is associated
with QTc segment elongation, and the potential increased risk of cardiac arrest and arrhythmia.39
Amisulpride 5 mg intravenously is efficacious as prophylaxis for PONV and reducing the
seriousness of nausea and vomiting.12 Its administration causes a minor raise in levels of
prolactin, with unclear clinical importance; at a standard dose, it does not cause mental status
changes, extrapyramidal symptoms, or QTc interval elongation.24-27 When intravenous
amisulpride is administer after induction of anesthesia, combined with another antiemetic, the
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occurrence of PONV was significantly decreased high-risk patients, undergoing surgical
procedures with administration of volatile anesthetics.24,25
III. Purpose and PICO Clinical Question
Purpose
The purpose of this project was to create and present an educational module to anesthesia
providers about the advantages of intravenous administration of amisulpride over ondansetron,
for the prevention of postoperative nausea and vomiting.
PICO Clinical Question
In patients undergoing surgery under general anesthesia (P), what is the effect of
intravenous amisulpride (I) compared to ondansetron (C) on preventing postoperative nausea and
vomiting (O)?
Population (P): Patients undergoing surgery under general anesthesia
Intervention (I): Intravenous amisulpride
Comparison (C): Ondansetron
Outcomes (O): Prevention of postoperative nausea and vomiting
IV. Conceptual Underpinning and Theoretical Framework
Goals and Outcomes
The SMART model will guide the goals and outcomes of this program. The objectives
must be specific, measurable, achievable, relevant, and time-based as a measure of significance,
feasibility, and quality.37
Specific
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Anesthesia providers will participate in an evidence-based educational module discussing
the etiology, risk factors, and consequences of PONV and how to prevent it with the
administration of intravenous amisulpride.
Measurable
The success of the educational module will be determined through the examination of a
survey that will be offered to the participants in the study. Outcomes will be evaluated based on
the pre- and posttest questionnaire, knowledge on how to identify PONV and its risk factors, the
consequences for the surgical patient and dose of amisulpride used to prevent PONV. A
template from a software (Qualtrics) generated the surveys and evaluate data points.
Achievable
Anesthesia practitioners were educated on the causes of PONV in the surgical patient,
extrinsic and intrinsic factors that contribute to PONV and its magnitude, and how to administer
intravenous amisulpride as prophylaxis of PONV.
Realistic
Anesthesia providers will be educated on PONV and its treatment based on recent
research by the student registered nurse anesthetist (SRNA). A PowerPoint presentation guided
the educational encounter, and a test questionnaire was offered before and after the education.
Time-Based
The educational program was developed over a 6-month period. With the successful
implementation of this educational module, anesthesia providers had a higher knowledge on
PONV: etiology, risks, and consequences, as well as treatment options including the
administration of intravenous amisulpride as prophylaxis of PONV.
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Program Structure/SWOT Analysis
An educational module on postoperative nausea and vomiting was developed and
provided to anesthesia providers. It was guided by an organizational assessment that helped
identify areas of lack of knowledge and internal and external variables that can impact and
influence in the success of the module. The strengths, weaknesses, opportunities, and threats
were analyzed and compared to the program goals to estimate feasibility and risks. The
participants in this educational module are anesthesiologists and nurse anesthetist, to whom a
survey was provided to complete before and after the educational module, to evaluate
comprehension.
This project sought to determine anesthesia providers’ knowledge of postoperative
nausea and vomiting, specifically etiology, diagnosis, prevention, and treatment. The
understanding on all these areas was measured through an initial questionnaire. Then, the
educational module was provided addressing all the aforementioned areas of postoperative
nausea and vomiting. A PowerPoint presentation was the primary delivery method, making the
module more interactive and dynamic. After the module was finished, another questionnaire was
provided to measure the new knowledge acquired; then, the two surveys were tabulated and
compared.
Strengths
Studies have shown the negative impact on patients who suffer postoperative nausea and
vomiting after a surgical procedure.37 PONV may contribute to dehydration, electrolyte
abnormalities, delayed wound healing and dehiscence, pulmonary aspiration of gastric content,
and extended hospital stay.1,2 Despite the widespread use of short-acting anesthetic agents,
antiemetic drugs as prophylaxis, and minimally invasive procedures, PONV still affects about
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20% to 30% of surgical patients. It could be as high as 80% in high-risk patients.3 One of the
reasons why there is a high incidence of PONV is the increased number of ambulatory surgical
procedures.3 There is an extensive repertoire of literature supporting strategies to prevent PONV,
but the optimal recommendation has not been established.2
Weaknesses
As an internal issue that may be a negative impact to the program is the anesthesia
providers’ lack of update information about prophylaxis options for postoperative nausea and
vomiting, especially those who do not use any drug to try to mitigate this postoperative
complication. PONV will occur in one-third of patients who do not receive prophylaxis, but
depending on the risk factors, the incidence can be as high as 80%.38
Ondansetron remains the drug of choice for prevention and treatment of PONV.5
Ondansetron hydrochloride is a selective inhibitor of type 3 serotonin receptors or 5HT3 receptors. It is preferred over other antiemetics by most anesthesia. When used as a
prophylaxis of PONV in adults, a 4 mg intravenous dose is recommended at least 30 minutes
before emergence from anesthesia. The half-life of ondansetron is usually about 4 hours;
therefore, it is recommended to administer it towards the end of the surgical procedure.5 There
are several side effects, with headache, dizziness, diarrhea, elevated liver enzymes, and
constipation being the most common.
Ondansetron is associated with QTc segment elongation, and the potential increased risk
of cardiac arrest and arrhythmia.39 Ondansetron was proven to be less efficacious than
ramosetron, granisetron, palonosetron, aprepitant, and fosaprepitant. Despite these facts,
ondansetron continues to be the first choice, even when superior drugs are available.9
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Opportunities
Amisulpride is a dopamine D2, D3 receptors antagonist. Amisulpride 5 mg intravenously
was found to be more effective than placebo in achieving a complete response and reducing the
severity of nausea.9 Administration of amisulpride has been associated with a mild increase in
levels of prolactin, but the clinical importance remains unclear. A standard antiemetic dose of
amisulpride it is not associated with sedation, extrapyramidal side effect, or QTc segment
prolongation.24-27
When intravenous amisulpride is given at induction of anesthesia in combination with a
standard antiemetic significantly decreases the incidence of PONV in a population of patients at
high risk of PONV undergoing a broad range of surgeries under general anesthesia using volatile
agents.24,25 Amisulpride, when used in combination with other class antiemetics, is well-tolerated
and has similar results compared to placebo in respect of safety profile.25 The effectiveness of
amisulpride as prophylaxis for PONV is higher when combined with dexamethasone than with
ondansetron.25
Threats
Several factors may harm the development and successful implementation of this
program, as well as the adoption of new treatment strategies for PONV like the use of
intravenous amisulpride as a prophylactic agent.9 The high cost of new medications and
quality healthcare is one of the most pressing issues to resolve if we are to bring health
services to every American. Absent change that creates an accessible system, the quality of
patient safety and outcomes are compromised. 27 The price of healthcare provided by
institutions is determined by the marketplace. National and local regulations are enacted to
control and monitor the cost of healthcare services, but too often, these regulations
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negatively impact the quality of care. As price becomes more accessible, the disparity
between cost and quality of care too often increases.
The application of evidence-based practice approaches to health care services is
perceived as optional. Yet, many providers lack knowledge or access to current evidentiary
information and so evidence-based practice is not applied in their patient care. Others simply
refuse to adopt new practices, contributing to an inherent weakness in the healthcare system.
Currently, patient care is moving towards an approach that relies on proven scientific evidence to
form solid arguments for guidance and decision-making.40 Still, some practitioners, based on
perpetuated methods, trust in tradition, intuition, or other unproven processes.41 Understanding
and applying evidence-based practices in the clinical environment challenges outmoded
traditional practices that create a gulf between previous methods and current research.42
Organizational Factors
The development and implementation of the PONV educational module was conducted
under the guidance of an interdisciplinary team. Several steps guided the development of the
module. The achievement of the program goals were measured by comparing and analyzing the
data collected. We provided a posttest questionnaire in the evaluation period, and it calculated
the effectiveness of this program. Recommendations to this program will follow, based on these
results, to improve its quality and efficacy.
Theoretical Framework
The healthcare environment continues to change. Scientific knowledge and practice
evolve and expand at an exponential rate to provide safe and high-quality patient care while
keeping healthcare institutions viable. Innovation is necessary for long-term success, and
organizations must be adaptable to change to succeed. 43 The identification and application of
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new knowledge into clinical practice is a transformative process that allows for the adoption of
evidence-based practice (EBP) within an organization. There are several organizational theories
of change. Lewin’s Force Field Analysis is a model consisting of three phases of change that can
be used to translate EBP within organizations.44
In the unfreezing phase of Lewin’s theory, the publication and distribution of current
information exposing the consequences of postoperative nausea and vomiting among
practitioners will propel understanding and behavior modification. Information about the use of
amisulpride as new antiemetic must be provided, as many practitioners do not use safer
alternatives due to a lack of knowledge.44 In the moving (or changing) phase, the practitioners in
the organization will prescribe more effective and safer alternatives to prevent PONV and
inhibiting influences like lack of knowledge about new options or wide availability of traditional
“not as good” choices, creating a new equilibrium between these positive and negative
elements.44 If this dynamic evolution continues, the third phase, refreezing, must happen to
maintain the positive changes achieved, because of the adoption of new protocols and guidelines
supporting the use of amisulpride versus ondansetron, for example, as a safer way to prevent
PONV.44
V. Methodology
Setting and Participants
The primary setting for this DNP project was a large level 1 trauma center in South
Florida, providing anesthesia services 24 hours a day by certified registered nurse anesthetists
and anesthesiologists. Anesthesia providers are involved in approximately 25,000 surgical
procedures annually.45
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Approval through the International Review Boards (IRB) was requested for this project.
Email addresses from future participants (anesthesia providers) were requested and used to send
links to the pretest, the educational module, and the post-education questionnaire. All the
participation is anonymous and voluntary.
Intervention and Procedures
This educational intervention sought to improve the anesthesia providers’ knowledge of
postoperative nausea and vomiting, especially its etiology, diagnosis, and prophylaxis. The
enhancement, creation, and dissemination of knowledge will follow a timeline, and it will adhere
to standards protocols. The plan after submission and approval by Florida International
University was submitted to the Anesthesia group, for which an IRB waiver would be expected.
An individualized and nontransferable link will be sent to anesthesia providers
(Anesthesiologists and CRNAs) as a distribution method for the pre- and post-questionnaires,
and for the educational module. A voiceover PowerPoint was used to present the educational
module. Questions and concerns were addressed by the author, and email and phone number
were also provided for future communication if needed.
Protection of Human Rights
Identifiers from anesthesia providers participating in this project were not collected or
stored. No personal or medical record was accessed for data extrapolation. All questionnaire
responses remained anonymous, protecting the right and privacy of all participants in this
project. Potential benefits to participants included improved knowledge on postoperative nausea
and vomiting and how to prevent, diagnose and treat. No harm, risk or any discomfort was
anticipated to be suffered from any of this project’s participants.
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Data Collection
A voiceover PowerPoint was used to provide information to meet the project goals, and
data was collected during this presentation. Demographic information was requested, voluntarily,
in the pretest. This included ethnicity, race, gender, as well as high level of education. The
number of participants was expected to be around 15 anesthesia providers, working within the
trauma center. Following consent, their knowledge will be recorded through the pre- and posttest.
Both pre- and posttests consisted of approximately 15 questions focusing on etiology, diagnosis,
and prevention of postoperative nausea and vomiting. Surveys were generated and disseminated
via Qualtrics and exported into Excel for comparison between the pre- and posttests. IRB standards were followed to guarantee the validity and reliability of data collected.
Data Management/Analysis
The database was password protected, and only the primary author had access to the data.
No participant identifiers were collected, nor associated with any data entered and analyzed. A
comparative analysis through Excel from Microsoft Software helped determine the anesthesia
provider previous knowledge on PONV and the degree of learning acquired after the educational
module.
V. Results
Demographics
The participants’ demographic characteristics are illustrated in Table 1. A total of 22
anesthesia providers from the anesthesia group at this trauma center completed, after agreed
informed consent, the pre-test survey, the educational module video presentation, and the
posttest survey. The average age of the anesthesia providers was 40 years; 10 of the participants
(45.45%) identified themselves as male and 12 (54.55%) as female. There were also a range of
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ethnicities represented: Caucasian (n = 9, 40.91%), Hispanic (n = 8, 36.36%), African American
(n = 2, 9.09%), Asian (n = 2, 9.09%) and West Indian (n = 1, 4.55%). All the participants (n =
22, 100%) were Certified Registered Nurse Anesthetists (CRNAs); 11 of them (50%) hold the
Master of Science in Nursing (MSN) Degree while the other 11 (50%) hold a Doctor in Nursing
Practice (DNP) Degree. The participants were questioned about the length of time practicing
anesthesia, finding that the practice period ranged: up to 2 years (n = 6, 27.28%), 3 to 5 years (n
= 4, 18.18%), 6 to 10 years (n = 4, 18.18%) and more than 10 years (n = 8, 36.36%).
Table 1. Participants’ Demographics
Participants (N = 22)
Gender
Male
Female
Ethnicity
Caucasian
African American
Hispanic
Asian
West Indian
Position
CRNA
Level of Education
MSN
DNP
Years of Experience
0–2
3–5
6 – 10
Over 10

Number

%

10
12

45.45
54.55

9
2
8
2
1

40.91
9.09
36.36
9.09
4.55

22

100

11
11

50
50

6
4
4
8

27.28
18.18
18.18
36.36

Pretest Knowledge of PONV Incidence and Complications
Questions based on most common inquiries about the incidence and associated
complications of Postoperative Nausea and Vomiting (PONV) were used to evaluate the
participants’ baseline knowledge about PONV and are shown in Table 2. The pretest survey
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results revealed knowledge deficits in most of the questions per the data scores on each
individual question.
The first question asked how high the incidence of PONV can be in patients undergoing
surgery under general anesthesia. Two providers (9.09%) answered wrongly “20%.” Three
providers (13.64%) also responder incorrectly “40%.” Ten providers (45.45%) responded
“60%,” while only 7 providers (31.82%) responded correctly “80%.”
Providers were asked by how many times the administration of opioids intraoperatively,
can increase the incidence of PONV. Two providers (9.09%) answered “1 to 2 times,” 13
CRNAs (59.09%) answered correctly “2 to 4 times,” 7 CRNAs (31.82%) answered “5 to 6
times.” When asked about the possible complications that could arise in patients suffering from
PONV, 2 participants (9.01%) chose “wound dehiscence” while 20 participants (90.91%) chose
“all of the above” (that included: wound dehiscence, unplanned hospital admission, aspiration,
and dehydration).
Pretest Knowledge Related to PONV Treatment
When asked about adverse drugs reactions of ondansetron, 100% of the participants (22)
answered correctly “Q.T. prolongation.” The providers were also asked about the mechanism of
action of amisulpride, 6 (27.28%) of them answered serotonin receptors antagonism, 7 (31.82%)
correctly answered dopamine receptor antagonism, 4 (18.18%) of them related the effects to
histamine receptors antagonism, and 5 (22.72%) of them to NK1 receptor antagonism.

A group of statements were offered to the participants and asked to identify the incorrect
one related to the intravenous administration of amisulpride. When asked if amisulpride “does
not” mildly increase prolactin levels, 6 (27.28%) participants choose this option. When asked if
amisulpride “does not” cause Q.T. prolongation, 11 (50%) participants correctly select this
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option. 1 (4.55%) provider choose “Effective in patients with 2+ PONV risk factors” while 4
(18.18%) chose “No sedation or extrapyramidal symptoms.”
Anesthesia providers were asked to identify the standard intravenous dose for prophylaxis
of PONV. None of the participants answered 1 mg or 20 mg. 21(95.45%) of the providers
correctly choose 5 mg. While 1 (4.55%) provider choose 10 mg as an answer. The
providers were asked to select “True or false” for the following statement: “Amisulpride 5 mg IV
is an efficacious PONV prophylactic dose”. 20 (90.90%) providers choose “true” white 2 of
them (9.10%) selected False.
Pretest Attitude Related to Use of Amisulpride
The participants were asked about the likelihood of using amisulpride as a prophylactic
agent for PONV. 8 participants choose “extremely likely” to use amisulpride as a preventive
agent for PONV. “Somewhat likely” was selected by 6 anesthesia providers, while 4 answered to
be “neither likely nor unlikely.” Three providers answered: “somewhat unlikely” to use
amisulpride while one selected “extremely unlikely.”
Pretest Attitude Related to Providers’ Recommendation of Amisulpride
The anesthesia providers were asked about the likelihood recommending the using
amisulpride as a prophylactic agent for PONV. Seven participants choose “extremely likely” to
use amisulpride as a preventive agent for PONV. “Somewhat likely” was selected by 6
anesthesia providers, while 3 answered to be “neither likely nor unlikely.” Three providers
answered: “somewhat unlikely” to use amisulpride while no one was “extremely unlikely.”
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Posttest Knowledge of PONV Incidence and Complications
Pre- and posttest knowledge questions regarding PONV incidence and complications are
illustrated in Table 2. When asked how high the incidence of PONV can be in, patients
undergoing surgery under general anesthesia. Two providers (9.09%) answered incorrectly
“40%.” Three providers (13.64%) also responder incorrectly “60%,” while 17 providers
(77.27%) responded correctly “80%.” After the educational module the correct answer by
providers increased by 45.45%.
Providers were asked by how many times, the administration of opioids intraoperatively,
can increase the incidence of PONV. One provider (4.55%) answered “1 to 2 times,” 13 CRNAs
(59.09%) answered correctly “2 to 4 times,” 5 CRNAs (22.72%) answered “5 to 6 times,” and 3
CRNAs (13.64%) answered “8 to 10 times.” The number of participants that responded correctly
to this question (59.09%) remained unchanged after the educational module.
When asked about the possible complications that could arise in patients suffering from
PONV, 1 participant (4.55%) chose “aspiration” while 21 participants (95.45%) chose “all of the
above” (that included: wound dehiscence, unplanned hospital admission, aspiration, and
dehydration). The percentage of correct participants for this question increased by 4.45%.
Table 2. Knowledge of PONV Incidence and Complications
Question
1. Depending on patient risk factors, the incidence
of PONV can be as high as:
20%
40%
60%
80% (*)
2. The administration of opioids intraoperatively
can increase the incidence of PONV by:
1 to 2 times
2 to 4 times (*)

Pretest

Posttest

% Change

2 (9.09%)
3 (13.64%)
10 (45.45%)
7 (31.82%)

0 (0%)
2 (9.09%)
3 (13.64%)
17 (77.27%)

9.09 ꜜ
4.55 ꜜ
31.81 ꜜ
45.45 ꜛ

2 (9.09%)
13 (59.09%)

1 (4.55%)
4.54 ꜜ
13 (59.09%) 0
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5 to 6 times
8 to 10 times
3. Untreated PONV can lead to:
Wound dehiscence
Unanticipated hospital admission
Aspiration
Dehydration
All of the above (*)
(*) Correct Answer

7 (31.82%)
0 (0%)

5 (22.72%)
3 (13.64%)

9.1 ꜜ
13.64

2 (9.09%)
0 (0%)
0 (0%)
0 (0%)
20 (90.91%)

0 (0%)
0 (0%)
1 (4.55%)
0 (0%)
21 (95.45%)

9.09 ꜜ
0
4.55 ꜛ
0
4.54 ꜛ

Posttest Knowledge Related to PONV Treatment
When asked about adverse drugs reactions of ondansetron 20 (90.90%) participants, as
illustrated in Table 3, answered correctly “Q.T. prolongation.” This represents a 9.09% decrease
when compared to with the pretest survey. This time, 1 provider (4.55%) responded incorrectly
“aPTT prolongation,” while another one (4.55%) answered Hyperglycemia. The providers were
also asked about the mechanism of action of amisulpride, 4 (18.18%) of them answered
serotonin receptors antagonism, 16 (72.72%) correctly answered dopamine receptor antagonism,
1 (4.55%) of them related the effects to histamine receptors antagonism, and 1 (4.55%) of them
to NK1 receptor antagonism.
A group of statements were offered to the participants and asked to identify the incorrect
one related to the intravenous administration of amisulpride. When asked if amisulpride “does
not” mildly increase prolactin levels, 1 (4.55%) participant choose this option. When asked if
amisulpride “does not” cause Q.T. prolongation, 20 (90.90%) participants correctly select this
option. This represents a 40.9% improvement in this area when compared to the pretest survey.
One (4.55%) provider chose “No sedation or extrapyramidal symptoms,” while no one chose
“Effective in patients with 2+ PONV risk factors.”
Anesthesia providers were asked to identify the standard intravenous dose for
prophylaxis of PONV. None of the participants answered 1 mg or 20 mg. Nineteen (86.36%) of
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the providers correctly choose 5 mg, while 3 (13.64%) providers choose 10 mg as an answer.
This represents a decline by 9.09% this correct answer. The providers were asked again to select
“true or false” for the following statement: “Amisulpride 5 mg IV is an efficacious PONV
prophylactic dose”. 20 (90.90%) providers choose “true,” while 2 of them (9.10%) selected
False, remaining unchanged when compared to the pretest survey.
Table 3. Knowledge of PONV Treatment
Question
4. Adverse drug reactions of Ondansetron (Zofran)
include:
Nausea
aPTT prolongation
QT prolongation (*)
Hyperglycemia
5. Amisulpride prevent PONV by antagonizing:
Serotonin receptors
Dopamine receptors (*)
Histamine receptors
NK1 receptors
6. Which of the following is incorrect regarding the
administration of Amisulpride?
Mildly increase in prolactin levels
QT prolongation (*)
Effective in patients with 2+ PONV risk factors
No sedation or extrapyramidal symptoms
7. Standard IV dose of Amisulpride is:
1 mg
5 mg (*)
10 mg
20 mg
8. Amisulpride 5 mg IV is an efficacious PONV
prophylactic dose.
True (*)
False
(*) Correct Answer

Pretest

Posttest

% Change

0 (0%)
0 (0%)
22 (100%)
0 (0%)

0 (0%)
1 (4.55%)
20 (90.90%)
1 (4.55%)

0
4.55ꜛ
9.09ꜜ
4.55ꜛ

6 (27.28%)
7 (31.82%)
4 (18.18%)
5 (22.72%)

4 (18.18%)
16 (72.72%)
1 (4.55%)
1 (4.55%)

9.1ꜜ
40.9ꜛ
13.63ꜜ
18.17ꜜ

6 (27.28%)
11 (50%)
1 (4.55%)
4 (18.18%)

1 (4.55%)
20 (90.90%)
0 (0%)
1 (4.55%)

22.73ꜜ
40.9ꜛ
4.55ꜜ
13.63ꜜ

0 (0%)
21(95.45%)
1 (4.55%)
0 (0%)

0 (0%)
19 (86.36%)
3 (13.64%)
0 (0%)

0
9.09ꜜ
9.09ꜛ
0

20(90.90%) 20(90.90%)
2 (9.10%)
2 (9.10%)

0
0
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Posttest Attitude Related to Use of Amisulpride
The participants were asked about the likelihood of using amisulpride as a prophylactic
agent for PONV after watching the educational module. (See Figure 2). This time, 16
participants choose “extremely likely” to use amisulpride as a prophylactic agent for PONV; this
is a 100% increase from the pretest survey. “Somewhat likely” was chosen by 3 anesthesia
providers, while 3 answered to be “neither likely nor unlikely.” No one answered “somewhat
unlikely” or “extremely unlikely.”
Figure 2. How likely are you to use intravenous amisulpride to prevent PONV?

How likely are you to use intravenous amisulpride to prevent PONV?
Pre-test
Post-test
18
16
16
14
12
10
8
8
6
6
4
3

4

3

3
1

2
0

0

0
Extremely Likely

Somewhat likely

Neither likely nor Somewhat unlikely
unlikely

Unlikely

Posttest Attitude Related to Providers’ Recommendation of Amisulpride
The last question asked to the anesthesia providers was about the likelihood
recommending the using amisulpride as a prophylactic agent for PONV (See figure 3). This time,
17 participants choose “extremely likely” to use amisulpride as a preventive agent for PONV,
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this represents a 45.45% increase from the pre-test survey. “Somewhat likely” was chosen by 3
anesthesia providers, while 2 answered to be “neither likely nor unlikely”. None of the providers
answered: “somewhat unlikely” nor “extremely unlikely.”
Figure 3. How likely are you to recommend the administration of intravenous Amisulpride as
prophylaxis of PONV?

How likely are you to recommend the administration of intravenous
Amisulpride as prophylaxis of PONV?
Pre-test
Post-test
17

18
16
14
12
10
8

7

6

6

6
3

4

2

3
0

0

0

0
Extremely Likely

Somewhat likely

Neither likely nor
unlikely

Somewhat unlikely

Unlikely

VI. Discussion
Limitations
Limitations of the study included the small sample size. Since the study was done in an
extensive healthcare system, a larger group would have been preferable in enhancing the strength
of the project. Time was another limitation for this project, since anesthesia providers were asked
to complete the posttest survey immediately after watching the educational module; a more
prolonged period would have been more benefitable in achieving better results. Lastly, the
delivery method was limited since it was all done in online platform and asynchronous mode.
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Despite these limitations, the findings of this project support the importance of educating
anesthesia providers on the effectiveness of intravenous amisulpride for prophylaxis of PONV.
Future Implications for Advances Nursing Practice
Evidence-based practice improve significatively the outcomes in the clinical practice and
combined with continuous education renew and strengthen the advance nursing knowledge while
increasing patient satisfaction.46 The significant impact of this intervention will provides
additional ability on Postoperative Nausea and Vomiting (PONV), a prevalent complication seen
in patients undergoing general surgery. At the same time, patient with a lower incidence, as well
as less severity of PONV, will experience better outcomes and a decrease in associated
complications related to PONV.
Conclusions
The literature review demonstrated that amisulpride has a safer profile when compared to
ondansetron, and it was transmitted in a form of virtual educational module to the anesthesia
providers. As the posttest results show, there is an improvement in most of the areas examined in
the questions asked to the participants. This Quality Improvement project met the objectives of
improving the anesthesia providers’ knowledge on PONV as well their expertise on ondansetron
and amisulpride as prophylactic drugs to reduce the incidence of PONV. The positive feedback
received after the educational module, about using and recommending amisulpride as
preventative method for PONV a successful intervention, not only in promoting, but in educating
about the advantages of intravenous amisulpride oven ondansetron for prophylaxis of
postoperative nausea and vomiting.
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Appendix C. Invitation to Participants

Advantages of intravenous administration of amisulpride over ondansetron for prophylaxis
of postoperative nausea and vomiting: An educational module.
Dear Broward Health ANESCO Anesthesia Provider:
My name is Odlanier Hebert, I am a student from the Anesthesiology Nursing Program
Department of Nurse Anesthetist Practice at Florida International University. I am writing to
invite you to participate in my quality improvement project. The goal of this project is to
improve health care provider knowledge on the advantages of intravenous administration of
amisulpride over ondansetron for prophylaxis of postoperative nausea and vomiting. You are
eligible to take part in this project because you are a member of the Anesthesia Department for
ANESCO at Broward General Medical Center.
If you decide to participate in this project, you will be asked to complete and sign a
consent form for participation. Next, you will complete a pre-test questionnaire, which is
expected to take approximately 5 minutes. You will then be asked to view an about 15-minutelong educational presentation online. After watching the video, you will be asked to complete the
post-test questionnaire, which is expected to take approximately 5 minutes. No compensation
will be provided.
Remember, this is completely voluntary. You can choose to be in the study or not. If
you'd like to participate or have any questions about the study, please email or contact me at
ohebe002@fiu.edu or (786) 329 0455.
Thank you very much.
Sincerely,
Odlanier Hebert, SRNA, BSN, CCRN
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Appendix D. Informed Consent

CONSENT TO PARTICIPATE IN A QUALITY IMPROVEMENT PROJECT
“Advantages of intravenous administration of amisulpride over ondansetron for prophylaxis of
postoperative nausea and vomiting: An educational module.”
SUMMARY INFORMATION
Things you should know about this study:









Purpose: Educational module to improve knowledge in utilizing amisulpride for
prophylaxis of Postoperative Nausea and Vomiting.
Procedures: If you choose to participate, you will be asked to complete a pre-test,
watch a voice PowerPoint and then a post test
Duration: This will take about a total of 20 minutes.
Risks: The main risk or discomfort from this research is minimal. There will be
minimal risks involved with this project, as would be expected in any type of
educational intervention, which may have included mild emotional stress or mild
physical discomfort from sitting on a chair for an extended period.
Benefits: The main benefit to you from this research is increase the participant’s
knowledge in utilizing amisulpride for prophylaxis of Postoperative Nausea and
Vomiting.
Alternatives: There are no known alternatives available to you other than not taking
part in this study.
Participation: Taking part in this research project is voluntary.

Please carefully read the entire document before agreeing to participate.

PURPOSE OF THE PROJECT
You are being asked to be in a quality improvement project. The goal of this project is to
improve anesthesia provider knowledge on the use of amisulpride for prophylaxis of
Postoperative Nausea and Vomiting.

NUMBER OF STUDY PARTICIPANTS
If you decide to participate you will be one of 10 participants under the purpose of the
project.
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DURATION OF THE PROJECT
Your participation will require about 20 minutes of your time.
PROCEDURES
If you agree to be in the project, we will ask you to do the following: Complete an online 10
question pre-test survey via Qualtrics, an Online survey product for which the URL link is
provided. Review the educational PowerPoint Module lasting 10 minutes via Qualtrics, an
Online survey product for which the URL link is provided. Complete the online 10 question
post-test survey via Qualtrics, an Online survey product for which the URL link is provided.
RISKS AND/OR DISCOMFORTS
The main risk or discomfort from this research is minimal. There will be minimal risks involved
with this project, as would be expected in any type of educational intervention, which may have
included mild emotional stress or mild physical discomfort from sitting on a chair for an
extended period of time, for instance.
BENEFITS
The following benefits may be associated with your participation in this project: An
increased understanding on the perioperative prevention of Postoperative Nausea and
Vomitinby g administering intravenous amisulpride as a prophylactic dpatiea ntspatient
undergoing surgery under general anesthesia.
The overall objective of the program is to increase the quality of healthcare delivery and
improve healthcare outcomes for our patients.
ALTERNATIVES
There are no known alternatives available to you other than not taking part in this project.
However, if you would like to receive the educational material given to the participants in this
project, it will be provided to you at no cost.
CONFIDENTIALITY
The records of this project will be kept private and will be protected to the fullest extent
providedby law. If, in any sor of report, we might publish, we will not include any information
that will make it possible to identify you as a participant. Records will be stored securely, and
only the project team will have access to the records.
PARTICIPATION: Taking part in this research project is voluntary.
COMPENSATION & COSTS
There is no cost or payment to you for receiving the health education and/or for participating in
this project.
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RIGHT TO DECLINE OR WITHDRAW
Your participation in this project is voluntary. You are free to participate in the project or
withdraw your consent at any time during the project. Your withdrawal or lack of participation
will not affect any benefits to which you are otherwise entitled. The investigator reserves the
right to remove you without your consent at such time that they feel it is in the best interest.
RESEARCHER CONTACT INFORMATION
If you have any questions about the purpose, procedures, or any other issues relating to this qual
y improvement project, you may contact Odlanier Hebert at 786-329-0455 or ohebe002@fiu.edu
and Yasmine Campbell at 305-348-9894 or ycampbell@fiu.edu.
IRB CONTACT INFORMATION
If you would like to talk with someone about your rights pertaining to being a subject in this
project or about ethical issues with this project, you may contact the FIU Office of Research
Integrity by phone at 305-348-2494 or by email at ori@fiu.edu.
PARTICIPANT AGREEMENT
I have read the information in this consent form and agree to participate in this study. I have had
a chance to ask any questions I have about this study, and they have been answered for me. By
clicking on the “consent to participate,” button below I am providing my informed consent.
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Appendix E. Data Collection Instrument (Pre- and Post-test Survey)

Pretest and Posttest Questionnaire:
Intravenous Amisulpride to Prevent Postoperative Nausea and Vomiting (PONV)
INTRODUCTION
The primary aim of this Q.I. project is to improve the knowledge of Anesthesia Providers
regarding the administration of intravenous Amisulpride (Barhemsys®) as prophylaxis for PONV
in patient older than 12 years old undergoing surgery under general anesthesia, to improve
patient outcomes in this population.
Please answer the question below to the best of your ability. The questions are either in
multiple choice or true/false format and are meant to measure knowledge and perceptions on
PONV and its prophylactic treatment by intravenous administration of Amisulpride.
PERSONAL INFORMATION
1. Gender: Male

Female

Other

2. Age:
3. Ethnicity:
Hispanic

Caucasian

African American

Asian

Other
4. Position/Title:
5. Higher Level of Education: MSN

DNP

MD

Other

6. How many years have you been an anesthesia provider?
Over 10 years

5-10 years

2-5 years

1-2 years
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QUESTIONNAIRE
1. Depending on patient risk factors, the incidence of PONV can be as high as:
a. 20%
b. 40%
c. 60%
d. 80%
2. The administration of opioids intraoperatively can increase the incidence of PONV
by:
a. One to two times
b. Two to four times
c. Five to six times
d. Eight to ten times
3. Untreated PONV can lead to:
a. Wound dehiscence
b. Unanticipated hospital admission
c. Aspiration
d. Dehydration
e. All the above
4. Adverse drug reactions of Ondansetron (Zofran) include:
a. Nausea
b. aPTT prolongation
c. Q.T. prolongation
d. Hyperglycemia
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5. Amisulpride prevents PONV by antagonizing:
a. Serotonin Receptors
b. Dopamine Receptors
c. Histamine Receptors
d. NK1 Receptors
6. Which of the following is INCORRECT regarding the administration of a standard
dose of intravenous Amisulpride for prevention of PONV?
a. Mildly increase in prolactin levels
b. Q.T. prolongation
c. Effective antiemetic effect in patients with 2 or more PONV risk factors
d. Does not cause sedation or extrapyramidal symptoms
7. Standard prophylactic dose of Amisulpride is a single intravenous bolus of:
a. 1 mg
b. 5 mg
c. 10 mg
d. 20 mg
8. Amisulpride 5 mg intravenously is efficacious as prophylaxis for PONV and
reducing the seriousness of nausea and vomiting. True or False.
a. True
b. False
9. How likely are you to use intravenous amisulpride to prevent PONV?
a. Most likely
b. Somewhat likely
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c. Somewhat unlikely
d. Most unlikely
10. How likely are you to recommend the administration of intravenous Amisulpride as
prophylaxis of PONV?
a. Most likely
b. Somewhat likely
c. Somewhat unlikely
d. Most unlikely

57
Appendix F. PowerPoint Presentation for Educational Module
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Appendix G. PowerPoint Presentation for Dissemination of Project
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Appendix H. Poster
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Appendix I. Presentation al 33rd International Nursing Research Congress
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